MedTrace Logo

5% and 15% Dextrose Prolotherapy Efficacy in Lateral Epicondylitis

NCT05066451 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2022-03-02

No results posted yet for this study

Summary

In the treatment of lateral epicondylitis, 5% dextrose prolotherapy is aimed to be more reliable than 15% prolotherapy in terms of side effects and to show that it is similar in terms of efficacy in treatment.

Conditions

  • Lateral Epicondylitis

Interventions

OTHER

%5 dextrose prolotherapy

Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week. Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact.

OTHER

%15 dextrose prolotherapy

Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week. Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact.

Sponsors & Collaborators

  • Istanbul Physical Medicine Rehabilitation Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Gokhan Taskin, MD · Istanbul Physical Medicine Rehabilitation Training and Research Hospita

  • Fatma Nur Kesiktas, Prof · Istanbul Physical Medicine Rehabilitation Training and Research Hospita

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-02-01
Completion
2022-02-25

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05066451 on ClinicalTrials.gov